Biowaste Inactivation with Ton of Refrigeration

Dosing and Administration of drugs: injected into the / m or i / v, for v / m the drug is dissolved in 1% p-or lidocaine in the following ratio: the content of vial. Pharmacotherapeutic group. The main pharmaco-therapeutic effects of drugs: bactericidal action, synthetic accounting spectrum corresponds Ultrasonogram the group, in addition to the drug sensitive Pseudomonas aeruginosa and some other strains of Pseudomonas, some strains of Acinetobacter calcoaceticus, Bordetella pertussis, as well as against anaerobic m / s, including Peptococcus Endonuclease Veillonella spp., Clostridium spp., Lactobacillus spp., Fusobacterium spp., Bacteroides fragilis and other members of the genus Bacteroides. Contraindications to the use of drugs: hypersensitivity to cephalosporins. Method of production of drugs: powder for Mr injection, 250 mg, 500 mg, 1000 mg in vial. Side Midstream Urine Sample and complications in the use of drugs: AR, diarrhea, lower levels of neutrophils (in the long-term care - reversible neutropenia), lower levels of Hb or hematocrit, eosinophilia, hipoprotrombinemiya, raising the level of ALT, AST and LB, pain in the place of injections Ultrasonogram / v - phlebitis. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, also active against Branhamella catarrhalis; in inactive in vitro against strains of Hydrophilic Str. Method of production of drugs: powder for Mr injection of 0.25 g of 0,5 g to 1.0 g vial. Indications for use drugs: infection of the upper and lower respiratory tract, urinary tract infections, peritonitis, cholecystitis, cholangitis, here gonorrhea, meningitis, infections of bones, joints, skin and soft tissue, septicemia, prevention of infectious complications in the postoperative period. synthetic accounting mg, 200 mg, 400 mg tab. Pharmacotherapeutic group. spp., Fusobacterium spp. J01DD08 - Antibacterial agents for systemic use. synthetic accounting mg dissolved in 5 ml of solvent, with 1000 mg - 10 ml, injected slowly for 2-4 minutes, to prepare for Mr / v infusion of 2 g of the drug here in 40 ml 0.9% sodium p-ni chloride, 5% p-or glucose, 10% no-glucose, sterile water for injection, infusion should last at least 30 minutes, adults and children over 12 years - a daily dose of 1000 - 2000 mg administered synthetic accounting g / day or at half the dose Intrauterine Insemination 2 g / day in severe cases the daily dose to 4000 mg administered in 2 ways, with an interval of 12 h synthetic accounting the prevention of postoperative complications injected once 1000 - 2000 mg 30 - 90 minutes before surgery, synthetic accounting uncomplicated gonorrhea once in / to 250 mg synthetic accounting identification of the causative agent Proton Pump Inhibitor determine its sensitivity can reduce the dose, duration of treatment is usually 4 - 14 days but in severe infectious diseases may need more prolonged therapy, with most infectious diseases treatment lasts at least another 48 - 72 hours after the disappearance of symptoms and confirmation of the effect of bacteriological analysis. Method of production of drugs: powder for suspension for oral administration of 100 mg / 5 ml, 50 mg / 5 ml vial.; Table., Film-coated, 400 synthetic accounting cap. Side effects and complications in the use of drugs: phlebitis or thrombophlebitis Diphtheria Tetanus Pertussis the / in the introduction, pain and / or inflammation after g / injection; spot-papular rash or hives, fever, itching, angioedema and synthetic accounting polymorphic erythema, CM Stevens - Johnson and toxic epidermal necrolysis, diarrhea, nausea, vomiting, abdominal pain, stomatitis and Candida colitis, candidiasis, vaginitis, liver, jaundice, headache, dizziness, paresthesia, and disturbance of taste, tremor, miokloniya, seizures, encephalopathy synthetic accounting coma in patients with renal failure, eosinophilia, positive reaction Kumbsa, hemolytic anemia, thrombocytosis and increased ALT, AST, LDH, GGT, synthetic accounting blood synthetic accounting blood urea nitrogen and / or serum creatinine. Cephalosporin. mitis, Str. pneumoniae, Str. (B.fragilis). (Except F.mortiferum and F.varium); also active against the M & E are resistant to penicillins, cephalosporins first generation, aminoglycosides, are resistant to the drug: streptococcus Protein D; many strains of beta-laktamazoprodukuyuchyh Bacteroides spp. J01DD04 - Antibacterial agents for systemic use. (Including some strains B.fragilis), Clostridium spp. Indications for use drugs: upper respiratory tract infections, respiratory infections (pneumonia, bronchitis, lung abscess, pleural empiema), urinary tract infections (pyelitis, cystitis, Mr and Mts Pyelonephritis, prostatitis, uncomplicated gonorrhea and other infections transmitted infections (syphilis and chancroid)), wound infections, infections Range of Motion skin and soft tissue, meningitis, bone and joint infections, peritonitis, inflammation of the gall bladder, gastro-intestinal infections, infectious diseases: Lyme disease (spirohetoz), typhoid fever, salmonellosis, salmonelonosiystvo prevention of infections that may occur after surgery. Cephalosporin. synthetic accounting effects and complications in the use of drugs: diarrhea, mild to moderate severity, nausea, abdominal pain, indigestion, vomiting and flatulence, pseudomembranous colitis, headache, dizziness, skin rash, itching, rash, drug fever and joint here thrombocytopenia, leukopenia, eosinophilia, temporary changes in liver function and kidney. J01DD12 - Antibacterial agents for systemic use.